N.E.W. Advisory Services LLC Takes $1.38 Million Position in Gilead Sciences, Inc. $GILD

Key Points

• N.E.W. Advisory Services LLC initiated a $1.38 million position in Gilead Sciences during the second quarter by purchasing 10,929 shares. Institutional investors collectively own 83.67% of the company.
• Gilead reported quarterly revenue of $7.80 billion, exceeding estimates, while revenue increased 10.6% year over year. The company declared a quarterly dividend of $0.82 per share, equating to a 2.4% annual yield.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and a $158.04 target price, although some analysts lowered their ratings or earnings forecasts. Recent growth has been supported by the HIV franchise, while oncology partnerships and pipeline developments offer longer-term potential.

N.E.W. Advisory Services LLC bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 10,929 shares of the biopharmaceutical company's stock, valued at approximately $1,381,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. grew its stake in shares of Gilead Sciences by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company's stock valued at $14,863,487,000 after buying an additional 2,113,692 shares during the period. State Street Corp grew its stake in Gilead Sciences by 1.9% in the fourth quarter. State Street Corp now owns 60,240,518 shares of the biopharmaceutical company's stock valued at $7,393,921,000 after acquiring an additional 1,151,213 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in shares of Gilead Sciences by 4.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 27,698,660 shares of the biopharmaceutical company's stock valued at $3,399,734,000 after acquiring an additional 1,195,269 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of Gilead Sciences by 15.2% during the fourth quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company's stock valued at $2,837,948,000 after acquiring an additional 3,046,688 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Gilead Sciences during the fourth quarter worth approximately $2,617,152,000. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Price Performance

GILD opened at $138.36 on Monday. Gilead Sciences, Inc. has a fifty-two week low of $108.46 and a fifty-two week high of $157.29. The firm has a market capitalization of $171.56 billion, a P/E ratio of -51.82 and a beta of 0.32. The company's 50-day moving average is $130.11 and its 200 day moving average is $136.44. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, beating the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The firm had revenue of $7.80 billion during the quarter, compared to analyst estimates of $7.40 billion. During the same quarter last year, the business posted $2.01 EPS. The company's revenue for the quarter was up 10.6% on a year-over-year basis. Research analysts expect that Gilead Sciences, Inc. will post -0.53 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date is Tuesday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is -122.85%.

Analyst Ratings Changes

GILD has been the topic of a number of recent research reports. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $155.00 price objective on shares of Gilead Sciences in a research note on Wednesday, August 5th. Leerink Partners downgraded Gilead Sciences from an "outperform" rating to a "market perform" rating and cut their price target for the company from $146.00 to $127.00 in a research note on Tuesday, July 21st. Maxim Group raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $165.00 price objective for the company in a research note on Wednesday, May 20th. Royal Bank Of Canada raised their target price on Gilead Sciences from $120.00 to $123.00 and gave the company a "sector perform" rating in a report on Wednesday, August 5th. Finally, Rothschild & Co Redburn cut their target price on Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Twenty-four investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Gilead Sciences currently has a consensus rating of "Moderate Buy" and a consensus target price of $158.04.

Insider Buying and Selling

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the business's stock in a transaction on Monday, June 15th. The stock was sold at an average price of $123.92, for a total value of $371,760.00. Following the transaction, the insider owned 124,234 shares of the company's stock, valued at approximately $15,395,077.28. The trade was a 2.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O'day sold 15,000 shares of the company's stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $130.31, for a total value of $1,954,650.00. Following the completion of the transaction, the chief executive officer owned 592,133 shares of the company's stock, valued at $77,160,851.23. This trade represents a 2.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 51,000 shares of company stock worth $6,568,860. 0.30% of the stock is owned by company insiders.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Appeals court ruling protects Gilead’s distribution channels. A U.S. appeals court upheld an injunction preventing alternative funding programs and related businesses from importing Gilead medications overseas. The decision could reduce the size of the alternative funding industry and help protect Gilead’s pricing, sales channels and patient-assistance economics. Court rules companies can't import Gilead medications from overseas in blow to AFP health programs
• Positive Sentiment: Q2 growth highlighted continued commercial momentum. Gilead’s HIV franchise led year-over-year sales growth, with Biktarvy and PrEP performing particularly well. Quarterly PrEP sales reportedly doubled to more than $1 billion, while Trodelvy, Livdelzi and progress in oncology and liver disease added to the growth outlook. 5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call
• Positive Sentiment: AI collaboration strengthens the oncology pipeline. Gilead partnered with Nucleai to use AI-powered tissue analytics in its antibody-drug-conjugate programs. The technology is intended to accelerate biomarker discovery and improve precision-oncology development. Gilead Sciences Expands ADC Research With AI Tissue Analytics
• Positive Sentiment: Merck partnership offers longer-term growth potential. Recent clinical and regulatory progress involving Gilead and Merck’s collaboration reinforces the possibility that the partnership could produce meaningful future growth in areas such as oncology and infectious disease. Could Merck and Gilead’s Partnership Create the Next Big Pharma Growth Engine
• Neutral Sentiment: Analysts and investors continue to debate whether Gilead remains attractively valued after its strong multiyear performance. High call-option activity signals bullish positioning but does not guarantee sustained gains.
• Negative Sentiment: An analyst reduced the FY2026 EPS forecast, potentially reflecting concerns about earnings normalization, expenses or pipeline investment. The revision may limit near-term upside despite Gilead’s solid revenue trends. FY2026 EPS Forecast for Gilead Sciences Reduced by Analyst

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source